Olympus will distribute Bard's GI (gastrointestinal) products:
This article was originally published in Clinica
CR Bard has formed exclusive agreements with Olympus Europe and KeyMed for the distribution of its disposable gastrointestinal and endoscopic accessories for gastroenterological procedures in Europe, the Middle East and Africa. The two companies are wholly-owned subsidiaries of Olympus Optical. Bard's endoscopic feeding devices are not covered by the agreement and will continue to be distributed by Bard.
You may also be interested in...
Officials from the US Food and Drug Administration cited their reasons for refusing to review new applications for companies with unresolved data integrity failures.
However, Vaccinex sees possible efficacy for SEMA4D inhibition in later-stage Huntington’s as well as Alzheimer’s disease. Pepinemab is also being studied with Keytruda in head-and-neck cancer.
In last year’s acquisition, Bristol Myers Squibb agreed to pay Celgene investors another $9 per share based on three approvals, including idecabtagene vicleucel (bb2121) by 30 March 2021.